PMID- 19523041
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20211020
IS  - 1369-1600 (Electronic)
IS  - 1355-6215 (Print)
IS  - 1355-6215 (Linking)
VI  - 14
IP  - 3
DP  - 2009 Jul
TI  - Modulation of MDMA-induced behavioral and transcriptional effects by the delta 
      opioid antagonist naltrindole in mice.
PG  - 245-52
LID - 10.1111/j.1369-1600.2009.00156.x [doi]
AB  - The delta opioid system is involved in the behavioral effects of various drugs of 
      abuse. However, only a few studies have focused on the possible interactions 
      between the opioid system and the effects of 3,4-methylenedioxymethamphetamine 
      (MDMA). In order to examine the possible role of the delta opioid system in 
      MDMA-induced behaviors in mice, locomotor activity and conditioned place 
      preference (CPP) were investigated in the presence of naltrindole (NTI), a 
      selective delta opioid antagonist. Moreover, the consequences of acute and 
      chronic MDMA administration on pro-enkephalin (Penk) and pro-opiomelanocortin 
      (Pomc) gene expression were assessed by real-time quantitative polymerase chain 
      reaction (QPCR). The results showed that, after acute MDMA administration (9 
      mg/kg; i.p.), NTI (5 mg/kg, s.c.) was able to totally block MDMA-induced 
      hyperlocomotion. Penk gene expression was not modulated by acute MDMA, but a 
      decrease of Pomc gene expression was observed, which was not antagonized by NTI. 
      Administration of the antagonist prevented the acquisition of MDMA-induced CPP, 
      suggesting an implication of the delta opioid receptors in this behavior. 
      Following chronic MDMA treatment, only the level of Pomc was modulated. The 
      observed increase was totally blocked by NTI pre-treatment. All these results 
      confirm the interactions between the delta opioid system (receptors and peptides) 
      and the effects of MDMA.
FAU - Belkai, Emilie
AU  - Belkai E
AD  - Laboratoire de Neuropsychopharmacologie des addictions (INSERM U705, CNRS UMR 
      7157), Universite Paris Descartes, Faculte de Pharmacie, 4 avenue de 
      l'Observatoire, Paris, France.
FAU - Scherrmann, Jean-Michel
AU  - Scherrmann JM
FAU - Noble, Florence
AU  - Noble F
FAU - Marie-Claire, Cynthia
AU  - Marie-Claire C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Addict Biol
JT  - Addiction biology
JID - 9604935
RN  - 0 (Enkephalins)
RN  - 0 (Hallucinogens)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Protein Precursors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Opioid, delta)
RN  - 0 (proenkephalin)
RN  - 5S6W795CQM (Naltrexone)
RN  - 66796-54-1 (Pro-Opiomelanocortin)
RN  - G167Z38QA4 (naltrindole)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Amphetamine-Related Disorders/*genetics
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Brain/drug effects
MH  - Choice Behavior/drug effects
MH  - Conditioning, Classical/drug effects
MH  - Enkephalins/*genetics
MH  - Gene Expression/drug effects/genetics
MH  - Hallucinogens/*toxicity
MH  - Mice
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Naltrexone/*analogs & derivatives/pharmacology
MH  - Narcotic Antagonists/*pharmacology
MH  - Pro-Opiomelanocortin/*genetics
MH  - Protein Precursors/*genetics
MH  - RNA, Messenger/genetics
MH  - Receptors, Opioid, delta/*antagonists & inhibitors
MH  - Social Environment
MH  - Transcription, Genetic/*drug effects
PMC - PMC2922624
MID - HALMS416565
OID - NLM: HALMS416565
EDAT- 2009/06/16 09:00
MHDA- 2009/09/25 06:00
PMCR- 2010/08/17
CRDT- 2009/06/16 09:00
PHST- 2009/06/16 09:00 [entrez]
PHST- 2009/06/16 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
PHST- 2010/08/17 00:00 [pmc-release]
AID - ADB156 [pii]
AID - 10.1111/j.1369-1600.2009.00156.x [doi]
PST - ppublish
SO  - Addict Biol. 2009 Jul;14(3):245-52. doi: 10.1111/j.1369-1600.2009.00156.x.